INTRODUCTION
The Reduced Expression in Immortalized Cells (REIC) gene is a member of the DKK family genes (hDKK-1,2,3 and 4) with homology to Xenopus laevis Dickkopf gene. REIC/Dkk-3 was originally isolated as an immortalization-related gene of normal human fibroblasts and was regarded as a tumor suppressor gene. 1, 2 The expression of the REIC/Dkk-3 gene is significantly reduced in a wide range of cancer cells. [3] [4] [5] [6] Although Dkk-3 does not bind with low-density lipoprotein-receptor-related protein 5/6 and the precise mechanism by which Dkk-3 interferes with Wnt signaling remains an obstacle, [7] [8] [9] its biological functions in the embryonic development 10, 11 and emerging roles in cancer therapy 2 have been studied with increasing attention. In addition, our previous study showed that REIC/Dkk-3 protein has a cytokinelike effect, responsible for the differentiation of human CD14+ monocyte into a novel cell-type, dendritic cell (DC)-like cell. 12, 13 An adenovirus vector carrying the human REIC/Dkk-3 gene (Ad-REIC) allowed the forced expression of REIC/Dkk-3, and induced apoptosis in a variety of cancer cells in vitro and in vivo. [14] [15] [16] [17] [18] The molecular mechanisms of these apoptotic events have been proved to be induced by unfolded protein response in the endoplasmic reticulum (endoplasmic reticulum stress) with c-Jun N-terminal kinase activation. [19] [20] [21] Interestingly, endoplasmic reticulum stress mediates the enhanced IL-7 expression in coinfected normal fibroblasts, resulting in the activation of innate immunity involving natural killer cells. 22 Furthermore, the secreted REIC protein with immunomodulatory function creates an optimal environment for the activation of host immune cells, inducing cytotoxic T lymphocytes (CTLs). 12, 13, 23 In the present study, we focus on the antigen-specific CTL responses mediated by in situ Ad-REIC gene therapy. Using a model of a tumor cell line carrying specific antigen, ovalbumin (OVA), we investigated in vivo antitumor effects via OVA-specific immune response generated by Ad-REIC gene therapy.
RESULTS

REIC/Dkk-3 induced apoptosis in E.G7 cell lines
The specific induction of apoptosis was demonstrated in E.G7 cells by Ad-REIC treatment. We first assessed the in vitro apoptotic effects of Ad-REIC in comparison with control vector, Ad-LacZ. E.G7 cells were infected with Ad-LacZ or Ad-REIC at 100 and 500 multiplicity of infection (MOI). We monitored apoptotic cells at 48 h after infection by Hoechst staining. The Ad-REIC vector significantly enhanced the in vitro apoptosis induction in comparison with the control vectors transfected at 500 MOI (Figures 1a and b) . At 500 MOI, 41.2 ± 8.64% of Ad-REIC-infected E.G7 cells were positive for Hoechst staining; in contrast, only 18.4 ± 4.16% of Ad-LacZ cells were positive (P o0.01).
In vivo Ad-REIC gene therapy suppressed the growth of E.G7 tumors We used an E.G7 mouse model to reveal the direct antitumor effects of Ad-REIC gene therapy (Figure 2a ). We first evaluated the levels of REIC/Dkk-3 protein expression in E.G7 tumors. The overexpression of REIC/Dkk-3 was observed after the intratumoral injection of Ad-REIC in E.G7 tumors; this response was not observed in control settings (Figure 2b ). We next investigated whether Ad-REIC inhibits tumor growth in vivo. The significant suppression of tumor growth was observed from day 10 in the Ad-REIC-treated group in comparison with the Ad-LacZ group (P o 0.01) (Figure 2c ).
Tumor antigen-specific CTLs were induced by Ad-REIC gene therapy We examined whether tumor antigen-specific CTLs could be induced by Ad-REIC gene therapy. E.G7 tumor-bearing mice were intratumorally injected with Ad-REIC or Ad-LacZ. Two days after the injection, the mice were killed and examined to determine whether OVA-specific CTLs had accumulated in the tumorinfiltrating lymphocytes (TILs). OVA-specific CTLs were detected by OVA tetramer comprising a major histocompatibility complex (MHC) H-2 Kb+OVA257-264. As shown in Figure 3a , a higher percentage of OVA tetramer+CD8+T cells was detected in the Ad-REIC-treated TILs in comparison with the control vector-injected mice (18.8% vs 3.4%, respectively; P = 0.02). We next evaluated the systemic immune response. After injection of the vector, the spleen was harvested and single-cell suspensions were prepared. Splenetic cells were cultured with OVA peptide for 7 days. After ex vivo OVA peptide stimulation, OVA-specific CTLs were detected by OVA tetramer. OVA tetramer+ cells were significantly higher in the Ad-REIC-treated spleen in comparison with the control mice (24.2% vs 1.1%, respectively; P = 0.04) (Figure 3b ). These results showed that Ad-REIC gene therapy significantly induced OVA-specific CTL responses in both the TILs and the lymphoid organs (Figure 3c ).
Induced CTL produce IFN-γ. To evaluate the production ability of interferon-γ (IFN-γ), CD8+ TILs and the tumor draining lymph nodes (TDLNs) were cultured with phorbol 12-myristate 13-acetate (PMA)/ionomycin for 4 h. PMA was a useful tool for monitoring the capacity for cytokine production of CD8+ T cells. 24 IFN-γ producing cells were not observed in Ad-LacZ-treated TILs and TDLN. The CTLs from Ad-REIC-treated mice produced large amounts of IFN-γ after PMA/ionomycin stimulation (Figures 4a and b) . As compared with Ad-LacZ, Ad-REIC gene therapy strongly induced IFN-γ production in CD8+ TILs and the TDLNs (TILs: 0.07 ± 0.11% vs 2.27 ± 0.63%, respectively; P = 0.02; TDLN: 0.18 ± 0.07% vs 2.34 ± 0.58%, respectively; P = 0.02) (Figure 4c ).
Characterization of DCs in the TDLN
To investigate the DC subsets after Ad-REIC treatment, TDLNs were removed and analyzed by flow cytometry. In the TDLNs, there were two subsets: CD11c int MHC class II high subset (mDC) and CD11c high MHC class II int subset (rDC). 25 In the Ad-REIC injection mice, more than 1.0 × 10 4 cells were mDCs and about 7.0 × 10 3 cells were rDCs. On the other hand, the number of cells in both DC subsets were o5.0 × 10 3 in Ad-LacZ-treated mice (Figure 5a ). CD103 (+) mDC and CD8 (+) rDC are known to have the ability of cross-presentation. [26] [27] [28] Significant amounts of induced DCs in Ad-REIC-injected mice were found to be subsets with the ability of cross-presentation (Figure 5b ). More importantly, in Ad-REIC-injected TDLNs, both DC subsets showed higher expression levels of CD86, which is used as an activation marker, in comparison with Ad-LacZ mice (Figure 5c ).
The systemic antitumor effect could be induced by in situ Ad-REIC gene therapy To assess the antitumor effects of Ad-REIC gene therapy on distant tumors, we developed a dual tumor-bearing mouse model (Figure 6a ). E.G7 cells were injected into the left and right back of a mouse. When the tumor diameter reached 5 mm, Ad-REIC was injected into the right side of the tumor only. Forty-eight hours after the second injection, the TILs were examined to detect OVA-specific CTLs. At 1 week after the second injection, complete tumor growth suppression was observed in the Ad-REIC-treated group, although the dual tumor grew in the Ad-LacZ-treated mice (Figure 6a ). To evaluate the indirect immune response, TILs were harvested from the non-injection side. As shown in Figure 6b , a significant number of OVA-specific CD8+ T cells were detected in non-injected tumor of Ad-REICtreated mice as compared with control Ad-LacZ-treated mice (11% vs 0.65%, respectively; P o 0.01) (Figure 6b ). In this dual tumor-bearing mouse model, it was confirmed that OVA-specific CTLs derived from Ad-REIC-injected tumor were responsible for antitumor effects on non-injected tumor. Using this model and anti-CD8 antibody to deplete the T-cell functions, we also confirmed that the antitumor effects were dependent on the CD8+ T lymphocyte, including the CTLs (Figures 6c and d) . We also examined the antitumor effects in the other dual tumorbearing mouse model of prostate cancer (PCa). Using human prostate-specific antigen (PSA)-expressing RM9 cancer cells, we further demonstrated the antitumor effects in the dual tumor (Figure 6e ).
DISCUSSION
The new strategy, based on the concept of simultaneous induction of selective killing of cancer cells and augmentation of antitumor immunity, leads to a new generation of cancer vaccines and it is expected to become a leading standard in the treatment of most solid cancers with gene therapy. To realize this concept, oncolytic viruses armed with granulocyte-macrophage colony-stimulating factor, such as T-VEC (talimogene laherparepvec, an oncolytic herpes simplex type 1 virus) and Pexa-Vec (pexastimogene devacirepvec; an oncolytic vaccinia poxvirus) have already been successfully developed. [29] [30] [31] Similarly, we are now developing Ad-REIC as a new therapeutic cancer vaccine using an original multifunctional therapeutic gene of REIC/Dkk-3.
In our preclinical and clinical studies on in situ gene therapy, indirect, systemic antitumor effects induced by Ad-REIC were found to be strong enough to be realized as therapeutic cancer vaccines. For instance, in an orthotopic PCa model with pre-established lung metastases using RM9 mouse PCa cells, intraprostatic injection of Ad-REIC significantly suppressed the local tumor growth and pre-established lung metastases, leading to a prolonged mice survival. 12, 32 The First-In-Man clinical study, a phase I/IIa study of in situ Ad-REIC gene therapy for PCa, was initiated at Okayama University (Okayama, Japan) in January 2011. 33 Two groups of patients were treated at four escalating doses: group A consisting of patients with castration-resistant PCa with or without metastasis, and group B consisting of patients with high-risk, localized PCa scheduled to undergo radical prostatectomy. As of November 2014, 8 patients in group A and 18 scheduled patients in group B were treated, demonstrating remarkable safety profiles of Ad-REIC. These clinical data with dose-dependent decrease in PSA (a tumor marker), immunopathological effects in surgical specimens and favorable outcomes in biochemical recurrence-free survival after radical prostatectomy in group B will be published elsewhere. In group A, marked systemic effects induced by in situ gene therapy were illustrated in a case of chemotherapy-resistant advanced castrationresistant PCa with bulky lymph node metastasis. 33 According to these preclinical and clinical results, we propose that the mechanism of action of in situ Ad-REIC is as follows: intratumoral injection of Ad-REIC induces massive apoptosis of cancer cells because of endoplasmic reticulum stress and provides an ideal presentation of possible cancer antigens to the host immune system. Secreted REIC protein at the tumor site creates an optimal environment, mediating tumor-associated, antigen-specific cytotoxic T cells. In addition, the overproduction of IL-7 by cancer-associated fibroblasts activates innate immunity involving natural killer cells. 22, 33 As the induction of activated DCs and antigen-specific CTLs is crucial for the development of therapeutic cancer vaccines by Ad-REIC, we investigated this process carefully in a mouse tumor model using E.G7-expressing OVA. The expression of REIC/Dkk-3 is lost in E.G7 tumors. In vitro susceptibility of E.G7 to Ad-REIC was low and a high MOI (500 MOI) was needed to induce sufficient apoptosis in the in vitro study (Figure 1) . Nevertheless, remarkable in vivo killing effects by Ad-REIC on subcutaneous E.G7 tumor were obtained (Figure 2) .
In general, naive CD8+ T cells interact with tumor-associated antigen-loaded allophycocyanins and acquire an effector function. 34 In this murine model, cell-associated OVA might be internalized by DCs in the treatment process of Ad-REIC and OVA peptide with the MHC class I was presented to naïve CD8+ T cells. The resulting OVA-specific CTLs were detected successfully by a peptide-MHC tetramer assay, which is the most reliable assay for investigating antigen-specific CTL (Figure 3 ). In addition, CD8+ T cells, including OVA-tetramer+ cells, showed IFN-γ production capacity, which is a functional surrogate marker for identifying peptide-specific CTL activity.
As cross-presentation is a critical step for the priming of effective anticancer T-cell responses, we performed an in vitro cross-presentation assay using OT-1 cells as indicated in our previous study. 35, 36 Unexpectedly, OT-1 cells showed poor IFN-γ production after coculture with DCs from Ad-REIC-treated mice (data not shown). Nevertheless, DCs were CD8+ rDCs and CD103+ mDCs phenotype, whose expression levels of CD86 were higher compared with those of DCs from control Ad-LacZ-treated mice ( Figure 5 ). CD86 is an activated marker and both CD8+ rDCs and CD103+ mDCs are known to have cross-presentation ability. Therefore, it is highly plausible that Ad-REIC gene therapy influences the cross-presentation pathway in DCs.
In our previous study, recombinant REIC/Dkk-3 protein with cytokine-like function was shown to induce the differentiation of human CD14+ monocytes into a novel cell-type, DC-like cells. 12 The intratumoral administration of REIC/Dkk-3 protein significantly suppressed subcutaneous RM9 tumor growth with CD11c+ and CD8+ (dendritic and killer T-cell marker, respectively) cell accumulation as determined by an immunohistochemical analysis. 12 Furthermore, a 17-kDa cysteine-rich core domain was recently shown to be sufficient for the induction of DC-like cell differentiation from monocytes. 13 Concomitant with the differentiation of DCs, the REIC/Dkk-3 protein induced the phosphorylation of glycogen synthase kinase-3β and signal transducers and Non-injected TILs were isolated on post-treatment day 2. All cells were stained with anti-CD8 and OVA tetramer beads and were analyzed by flow cytometry. The overall frequency of the OVA tetramer+ T cells in the non-injection side tumor. The P-value was calculated using the paired t-test. (c) The tumor growth curves and a macroscopic view of E.G7 tumor. The mean volume of the tumors was calculated and the tumor growth curves are shown. *A significant difference was observed between Ad-REIC group and the control vector groups. (d) The tumor growth curves of E.G7 tumor. The mean volume of the tumors was calculated and the tumor growth curves are shown. *A significant difference was observed in the directly treated tumor between Ad-REIC group and Ad-REIC plus anti-CD8 antibody-added groups.
† A significant difference was observed in the opposite (non-injected) tumor between Ad-REIC group and Ad-REIC plus anti-CD8 antibody-added groups. (e) The tumor growth curves of PSA-RM9 tumor. The mean volume of the tumors was calculated and the tumor growth curves are shown. *A significant difference was observed in the directly treated tumor between Ad-REIC group and the control vector groups. † A significant difference was observed in the opposite (non-injected) tumor between Ad-REIC group and the control vector groups.
Antitumor effects of Ad-REIC Y Ariyoshi et al activators of transcription 3 and at a level comparable to that of granulocyte-macrophage colony-stimulating factor. 13 According to these observations, it is possible that REIC/Dkk-3 protein secreted from tumors influences DC activation and differentiation.
Consequently, activated DCs in the TDLNs sufficiently induced OVA-specific CTLs, which circulated throughout the body and infiltrated into non-injected tumor in the present dual tumorbearing murine model ( Figure 6 ). In this process, CD8+ CTLs have essential roles in the antitumor effects based on the results with anti-CD8 antibody to deplete the T-cell functions. Using mouse PCa model with human PSA-expressing tumor, we further confirmed the generalizability of the current experiments in the other tumor type of PCa. Challenges for the routine detection of antigen-specific CTLs induced by Ad-REIC have not been successful in our phase I/IIa clinical trial in PCa. However, the present findings on OVA-specific CTLs induced by Ad-REIC in the E.G7 mouse model and on PSA-expressing tumor mouse model are extremely helpful to support our promising clinical results obtained and proposed action mechanism of in situ Ad-REIC to generate personalized therapeutic cancer vaccines.
MATERIALS AND METHODS
Mice and cell lines C57BL/6 female mice (ages: 6-8 weeks) were obtained from CLEA Japan. All mice were maintained under specific pathogen-free conditions in Okayama University. E.G7 is an OVA cDNA-transfected derivative of the EL4 (methylchoranthlene-induced thymoma of C57BL/6 [H-2 b ] origin) cell line. The E.G7 cells were kindly provided by Professor Udono. The E.G7 cells were maintained with RPMI-1640 containing 10% fetal calf serum, 2 mM L-glutamine, 1 mM sodium pyruvate, 0.1 mM non-essential amino acid, penicillin-streptomycin, 2-mercaptoethanol and 400 μg ml − 1 G418.
Adenovirus vector carrying REIC/Dkk-3
To induce the overexpression of REIC/Dkk-3, an adenovirus vector carrying the REIC/Dkk-3 gene (Ad-REIC) was created. A full-length cDNA was integrated into a cosmid vector pAxCAwt and transferred into an adenovirus vector using the COS-TPC method (Takara Bio, Shiga, Japan). An adenovirus vector carrying the LacZ gene (Ad-LacZ) was used as a control.
Apoptosis assay E.G7 cells (1.0 × 10 5 cells) were seeded in 6-well plates and incubated in culture medium for 24 h. The cells were then treated with Ad-LacZ or Ad-REIC at the indicated MOI in 2 ml of the medium. After 24 h of incubation, the apoptotic cells were visualized by Hoechst 33 342 staining, and the apoptotic rate was analyzed as described previously. 38, 39 Western blot analysis Total protein was extracted from the treated tumor tissue and western blotting was performed as described previously.
14 Proteins were identified with the use of the mouse monoclonal anti-human REIC/Dkk-3 antibody, which was raised in our laboratory, at 1000 × dilution.
In vivo experiments E.G7 cells were suspended in serum-free medium and inoculated intradermally into the left back of mice (1 × 10 6 cells in 200 μl). One week after injection, when the tumor reached~10 mm in diameter, Ad-REIC or Ad-LacZ was injected intratumorally at a dose of 1 × 10 9 PFU (pore-forming unit) in 40 100 μl of phosphate-buffered saline. Mice received a second injection of Ad-REIC or Ad-LacZ 2 days after the first injection. The size of the tumors was measured every 2 days. The tumor volume was calculated using an empirical formula, V = 1/2 × (the shortest diameter) × (the shortest diameter) × (the longest diameter). The experiments were perfomed according to the guidelines of Okayama University. In the CD8-depleting experiments, mice were anesthetized with ether, after which anti-Lyt-2.2 (CD8) antibody diluted in phosphate-buffered saline to a total dose of 200 μl per mouse was injected intraperitoneally. 24 In the other experiments, mouse PCa cell line, PSA-RM9, which is stably transfected and expresses human PSA, was used as described previously. 40 
Flow cytometric analysis
The following fluorochrome-labeled anti-mouse monoclonal antibodies were used. PerCP/Cy5.5-conjugated anti-mouse CD19 (BioLegend, San Diego, CA, USA), PE-Cy7-conjugated anti-mouse CD8α (BioLegend), allophycocyaninCy7-conjugated anti-mouse CD11c (BioLegend), FITC-conjugated anti-mouse MHC class II (I-A/I-E) (eBioscience, San Diego, CA, USA), PE-conjugated antimouse CD11b (BioLegend), allophycocyanin-conjugated anti-mouse CD103 (BioLegend) and phycoerythrin-conjugated anti-mouse CD86 (BioLegend) were used for the detection of DC populations. Cells were washed and incubated with monoclonal antibodies for 30 min at 4°C in 5 mM EDTA and phosphate-buffered saline containing 2% fetal calf serum (FACS buffer). All stained cells were acquired on a FACSCanto with the FACSDiva software program (BD Biosciences, Palo Alto, CA, USA) and analyzed using the FlowJo software program (TreeStar, San Carlos, CA, USA).
Tetramer assays
For the analysis of OVA-specific CTL frequency, lymphocytes were obtained from the spleen and TDLNs and TILs on day 2 after the last treatment. The TIL and TDLN cells were washed two times in FACS buffer and incubated with phycoerythrin-conjugated H-2K b OVA tetramer (MBL, Nagoya, Japan) for 30 min at room temperature. After tetramer staining, phycoerythrinCy7-conjugated anti-mouse CD4 (BioLegend) and allophycocyaninCy7-conjugated anti-mouse CD8α (BioLegend) were used for cell surface staining. After harvesting the splenocytes from the mice on the indicated days, the cells were coincubated with OVA257-264 peptide (SIINFEKL) for 5 days. The incubated cells were also stained by OVA tetramer and cell surface antibody. The frequency of OVA-specific CD8+ cells were analyzed on a FACSCanto II system.
Intracellular cytokine assay
For the DLN and naive T-cell intracellular cytokine staining, samples were restimulated with 50 ng ml − 1 PMA and 500 ng ml − 1 ionomycin (Sigma-Aldrich, St Louis, MO, USA) for 4 h. The cells were surface stained with allophycocyaninCy7-conjugated anti-mouse CD8α (BioLegend). The cells were washed, fixed and permeabilized with Cytofix/Cytoperm buffer and intracellular staining was performed with phycoerythrin-conjugated anti-mouse IFN-γ (eBioscience). Finally, The cells were analyzed with a FACSCanto II system.
Statistical analysis
All data expressed as the means ± s.e.m. and representative of at least two different experiments. The statistical differences between the groups were assessed by analyzing means of replicates using the two-tailed Student's t-test. A P-value of o0.05 indicated that the value of the test sample was significantly different from that of the relevant controls.
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